We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Slate Pharma Gets DDMAC Warning for Testosterone Drug Marketing
Slate Pharma Gets DDMAC Warning for Testosterone Drug Marketing
April 14, 2010
The FDA’s Division of Drug Marketing, Advertising and Communications (DDMAC) has cited Slate Pharmaceuticals for marketing claims that promote
unapproved uses of its testosterone drug Testopel, omit and minimize risk information, broaden its indication and overstate its efficacy.